Yesterday, the Food and Drug Administration's (FDA) advisory committee met to discuss Merck's (NYSE:MRK) experimental insomnia drug Suvorexant. While the committee did agree that the drug was effective at lower doses, there were some concerns over the side-effects associated with the medication at higher doses. In the following video, health-care analyst Max Macaluso discusses the results of the meeting, and how the ultimate FDA decision on Suvorexant can impact Merck's stock.
Unclear Future for Merck's Insomnia Drug
The FDA advisory committee has discussed Suvorexant; now shareholders need to get ready for the agency's final decision this summer.
Max Macaluso
(TMFMassimo)
May 23, 2013 at 6:30PM
Author Bio
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo
Motley Fool Returns
Stock Advisor
S&P 500
5 Years
57%
38%
17+ years
346%
95%
Stock Advisor launched in February of 2002. Returns as of 12/10/2019.
Join Stock Advisor